Ipamorelin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
Fomepizole, also known as 4-methylpyrazole, is a medication used to treat methanol and ethylene glycol poisoning. It may be used alone or together with hemodialysis. It is given by injection into a vein. Common side effects include headache, nausea, sleepiness, and unsteadiness. It is unclear if use during pregnancy causes risk to a fetus. Fomepizole works by blocking the enzyme that converts methanol and ethylene glycol to their toxic breakdown products. Fomepizole was approved for medical use in the United States in 1997. It is on the World Health Organization's List of Essential Medicines.
Suppress the release of neuropeptide Y (NPY), which in turn prevents the release of appetite enhancing orexins from the lateral hypothalamus. This decreases appetite and food intake, promoting weight loss. Stimulate the expression of cocaine and amphetamine regulated transcript (CART). Though rising blood levels of leptin do promote weight loss to some extent, its main role is to protect the body against weight loss in times of nutritional deprivation. Other factors also have been shown to effect long-term hunger and food intake regulation including insulin. In addition, the biological clock (which is regulated by the hypothalamus) stimulates hunger. Processes from other cerebral loci, such as from the limbic system and the cerebral cortex, project on the hypothalamus and modify appetite. This explains why in clinical depression and stress, energy intake can change quite drastically.
biotin) or clickable handles (azides or alkynes) enable enrichment of labeled enzymes prior to identification by liquid chromatography-tandem mass spectrometry (LC-MS/MS). After covalent labeling in cells or lysates, enzyme-probe adducts are captured using streptavidin or other affinity matrices, washed to remove unlabeled proteins, and digested for MS-based peptide identification. This strategy provides high sensitivity and depth of coverage, which facilitates the discovery of novel enzyme targets, detection of low-abundance enzymes and analysis of complex enzyme families. To compare enzyme activity across biological conditions, ABPP can be integrated with quantitative proteomic technologies to measure relative enzyme activity across samples. Techniques such as SILAC (Stable Isotope Labeling by Amino acids in Cell culture) incorporate heavy or light isotope-encoded amino acids into cellular proteins, facilitating direct MS-based comparison of probe-labeled peptides from different samples. TMT (Tandem mass tagging) which uses isobaric mass tags allows labeled peptides from multiple samples to be multiplexed and quantified simultaneously. These strategies have been widely applied to assess selectivity of covalent inhibitors and genome-wide changes in enzymatic activity. isoTOP-ABPP (Isotope Tagging of Optimized Probes for Activity-Based Protein Profiling) is a specialized workflow that was developed to address some of the limitations of conventional ABPP, including poor specificity, limited sensitivity, and the absence of selective chemical ligands for many human enzymes.
The Soviet military maintained control over the space program; Korolev's OKB-1 design bureau was subordinated under the Ministry of General Machine Building, tasked with the development of intercontinental ballistic missiles, and continued to give its assets random identifiers into the 1960s. Information about failures was systematically withheld, historian James Andrews notes that Soviet media coverage of the space program, particularly human space missions, rarely reported any failures or difficulties, creating the impression of a flawless operation:"With almost no exceptions, coverage of Soviet space exploits, especially in the case of human space missions, omitted reports of failure or trouble".Dominic Phelan noted in the book Cold War Space Sleuths (Springer-Praxis 2013): "The USSR was famously described by Winston Churchill as 'a riddle, wrapped in a mystery, inside an enigma' and nothing signified this more than the search for the truth behind its space program during the Cold War. Although the Space Race was literally played out above our heads, it was often obscured by a figurative 'space curtain' that took much effort to see through".
Disease-modifying antirheumatic drugs (DMARDs), such as hydroxychloroquine and methotrexate, may be used to try to slow the progression of disease. Biological DMARDs may be used when the disease does not respond to other treatments. However, they may have a greater rate of adverse effects. Surgery to repair, replace, or fuse joints may help in certain situations. Rheumatoid arthritis affects about 17.6 million people globally, as of 2020. This is 0.5–1% of adults in the developed world with between 5 and 50 per 100,000 people newly developing the condition each year. Onset is most frequent during middle age and women are affected 2.5 times more than men. It resulted in 38,300 deaths in 2020, up from 28,000 deaths in 1990. The first recognized description of RA was made in 1800 by Dr. Augustin Jacob Landré-Beauvais (1772–1840) of Paris. The term rheumatoid arthritis is based on the Greek words for watery and inflamed joints (from Ancient Greek ῥεῦμα (rheûma) 'flowing current', with arthritis derived from arthr- (meaning 'joint') and -itis (meaning 'inflammation')).
Sources: en.wikipedia.org
=== Rate of DNA replication === The rate of DNA replication in a mouse cell growing in vitro was measured by autoradiography as 33 nucleotides per second. The rate of phage T4 DNA elongation in phage-infected E. coli was also measured by autoradiography as 749 nucleotides per second during the period of exponential DNA increase at 37 °C (99 °F).
By size brevis means short; longus means long; longissimus means longest; magnus means large; major means larger; maximus means largest; minor means smaller, and minimus smallest; latissimus means widest, and vastus means huge. These terms are often used after the particular muscle such as gluteus maximus, and gluteus minimus. By relative shape deltoid means triangular; quadratus means having four sides; rhomboideus means having a rhomboid shape; teres means round or cylindrical, and trapezius means having a trapezoid shape; serratus means saw-toothed; orbicularis means circular; pectinate means comblike; piriformis means pear-shaped; platys means flat and gracilis means slender. Examples are the pronator teres, and the pronator quadratus. By action abductor moving away from the midline; adductor moving towards the midline; depressor moving downwards; elevator moving upwards; flexor moving that decreases an angle; extensor moving in a way that increases an angle or straightens; pronator moving to face down; supinator moving to face upwards; internal rotator rotating towards the body; external rotator rotating away from the body; sphincter decreases the size, and tensor gives tension to; fixator muscles serve to fix a joint in a given position by stabilizing the prime mover whilst other joints are moving. By number of heads biceps two; triceps three and quadriceps four. By location named after the near main structure such as the temporal muscle (temporalis) near to the temporal bone. Also supra- above; infra- below, and sub- under.
In 2019, the FDA warned consumers that kratom remains unapproved for interstate commerce for use as a drug, may be unsafe in commercially available products, and is on an import alert, which can lead to confiscation of imported supplies. Efforts to schedule kratom generated significant controversy, both among the general public and the scientific community, and were ultimately unsuccessful. In August 2025, Florida Attorney General James Uthmeier announced an emergency rule placing 7-hydroxymitragynine into Schedule I status under Florida state law, without any mention of a carve out or any exclusions for Mitragyna speciosa which contains low amounts of 7OH, effectively making kratom illegal in Florida. On April 10, 2026, Kansas Governor Laura Kelly signed a bill into law banning the sale and possession of all kratom products in the state, including 7-OH, effective July 1, 2026. North Dakota banned kratom, effective August 5, 2026, via an executive order from the governor and also an emergency rule from the pharmacy board. Subsequently, the legislature passed a law banning synthetic kratom but allowing natural kratom to be sold to those over 21, along with requiring labeling and imposing marketing restrictions. This law was signed by the governor on September 4th, but kratom is still banned until regulations under the new law are issued.
== Cultural Award of the State of Hesse (2009) == In 2009, following a temporary revocation of the award, Kermani received the Hesse Cultural Award — along with Cardinal Karl Lehmann; the former president of the Church of Hesse-Nassau; Peter Steinacker; and the vice president of the Central Council of Jews, Salomon Korn. That year's ceremony was held under the theme of interreligious tolerance. The prize was offered to Kermani on March 20, 2009, after the originally intended recipient, Fuat Sezgin, had declined to accept it on the grounds that his co-recipient, Salomon Korn, supported Israel's military actions. On May 13, 2009, Kermani learned that the award intended for him had been revoked. He went on, however, to describe how this view had been shaken by what he described as the aesthetic experience: "For the first time, I thought: I — not just 'one' — I could believe in a cross." On April 24, 2009, Lehmann stated in a letter to Hesse's Minister President Roland Koch that Lehmann "cannot accept the award under these circumstances". Commentators described Lehmann's tone as "subtly ... defamatory", "smug", "mean-spirited", and "condescending"; Kermani, too, found it "defamatory". In the end, after a conversation with Kermani, Lehmann and Steinacker decided to accept the award jointly. The award was ultimately presented to the four laureates on November 26, 2009. At the ceremony, Minister President Koch apologized to Kermani. Kermani donated his prize money to Franz Meurer, the pastor of the Catholic parish of St. Theodor in Cologne-Vingst.
Sources: en.wikipedia.org
=== Generic names === The English and generic name of CPA is cyproterone acetate and this is its USANTooltip United States Adopted Name, BANTooltip British Approved Name, and JANTooltip Japanese Accepted Name. The English and generic name of unacetylated cyproterone is cyproterone and this is its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while cyprotérone is the DCFTooltip Dénomination Commune Française and French name and ciproterone is the DCITTooltip Denominazione Comune Italiana and Italian name. The name of unesterified cyproterone in Latin is cyproteronum, in German is cyproteron, and in Spanish is ciproterona. These names of cyproterone correspond for CPA to acétate de cyprotérone in French, acetato de ciproterona in Spanish, ciproterone acetato in Italian, cyproteronacetat in German, siproteron asetat in Turkish, and cyproteronacetaat in Dutch. CPA is also known by the developmental code names SH-80714 and SH-714, while unacetylated cyproterone is known by the developmental code names SH-80881 and SH-881.
=== Neurodegenerative disorders === As suppression of autophagy has been indicated as a contributing factor in a variety of neurodegenerative disorders, including Alzheimer's disease, rapamycin has been proposed as a potential treatment for these conditions, although results suggest it may not be effective in all cases.
An individual with a transsexual or gender dysphoria diagnosis can, together with the assessment team and other doctors, decide what suits them. Medically transitioning in Sweden is covered by the high-cost protection for medications and doctor's visits, and there is no surgery fee. The fee the individual pays for a doctor's appointment or other care represents only a small fraction of the actual costs. If a person would like to change their legal gender marker and personal identity number they will have to seek permission from the National Board of Health and Welfare. For non-binary persons younger than 18 years, the healthcare is limited. These individuals do not have access to a legal gender marker change or bottom surgery. In Sweden, anyone is allowed to change their name at any time, including for gender transition. Up until January 27, 2017, being transsexual was classed as a disease. Two months earlier, on November 21, 2016, around 50 trans activists broke into and occupied the Swedish National Board of Health and Welfare (Swedish: Socialstyrelsen) premises in Rålambsvägen in Stockholm. The activists demanded that their voices be heard regarding the way the country, healthcare, and the National Board of Health and Welfare mistreat transgender and intersex individuals. Sweden's Karolinska Institute, administrator of the second-largest hospital system in the country, announced in March 2021 that it would discontinue providing puberty blockers or cross-sex hormones to children under 16.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.